Today: 11 June 2026
Salesforce stock tumbles nearly 7%: what CRM investors are watching next
13 January 2026
1 min read

Salesforce stock tumbles nearly 7%: what CRM investors are watching next

NEW YORK, Jan 13, 2026, 15:48 EST — Regular session

  • Salesforce (CRM) shares dropped roughly 7% in late-afternoon trading, standing out as one of the Dow’s largest decliners.
  • The drop coincides with a rush by companies to develop “AI agents” — software designed to perform tasks rather than just respond to queries.
  • Next, Salesforce will report earnings on Feb. 25 after the market closes, a crucial check on demand and guidance.

Salesforce shares dropped almost 7% Tuesday afternoon, deepening the selloff in one of the Dow’s most expensive stocks. By 3:48 p.m. EST, the stock had fallen 6.9% to $241.62.

The timing is rough. Investors have been banking on Salesforce’s claim that its new artificial intelligence tools will sustain growth, even as companies scrutinize their tech budgets down to the last dollar.

This matters because the stock’s sharp drop often ripples through other enterprise software shares. When a major player takes a hit this severe, traders usually see it as a signal on demand for “growth” stocks — companies priced on profits expected down the line.

Salesforce has launched a revamped Slackbot aimed at Business+ and Enterprise+ users, branding it as an AI agent, according to VentureBeat. CTO Parker Harris described it as a “Porsche.” Venturebeat

Anthropic’s competitors aren’t standing still. They rolled out Cowork, a feature in Claude Desktop enabling users to direct Claude to a folder for reading or editing files, TechCrunch reported.

The broader market struggled. U.S. stocks dipped following consumer price data that matched expectations, keeping rate-cut bets mostly unchanged, Reuters reported. Oliver Pursche, senior vice president at Wealthspire Advisors, described the move as “a little bit of letting the air out of the balloon” after recent record peaks.

Software stocks faced declines across the board. Adobe dropped 5.6%, ServiceNow slid 3.6%, Microsoft edged down 0.9%, and Oracle fell 1.6%.

Salesforce’s decline hit the price-weighted Dow hard. MarketWatch reported that drops in Salesforce and Visa together chopped about 194 points from the index earlier in the session.

Salesforce has shifted the narrative on AI and profit margins. In December, it boosted its fiscal 2026 revenue forecast to between $41.45 billion and $41.55 billion, while also raising its adjusted earnings guidance, citing strong demand for its AI products, Reuters reported.

The bar remains high. Customers often spend months testing AI tools before committing to larger contracts, and the costs of scaling automation can catch them off guard—whether in soaring compute bills, increased support demands, or slower rollouts within large companies.

Stock Market Today

  • North Atlantic Smaller Companies Investment Trust PLC AGM Results June 2026
    June 11, 2026, 10:59 AM EDT. North Atlantic Smaller Companies Investment Trust PLC (NASCIT) announced at its 11 June 2026 Annual General Meeting that all resolutions were passed with strong shareholder support. Key was Resolution 16, approved by 97.31%, allowing the Concert Party's shareholding to increase from 32.467% to a maximum of 36.074% without triggering a mandatory offer, following a share buyback authorized by Resolution 14. Total votes cast showed overwhelming majority approval, with most resolutions receiving above 95% support. This vote impacts NASCIT's share structure and potential control dynamics. The company can continue its share repurchase strategy while managing shareholder interests.

Latest articles

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

11 June 2026
TOVX soared 74.6% to $0.4252 after Theriva Biologics published Phase 1 VCN-01 data showing survival and biomarker signals in head-and-neck cancer, but the jump was not due to drug approval or revenue; investors face ongoing financing, dilution, and clinical-trial execution risks, with the company’s cash runway only into Q1 2027 and substantial doubt about its ability to continue as a going concern without new capital.
Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

11 June 2026
Trulieve began NYSE trading as TRLV this week after moving from OTC/CSE, authorized a buyback of up to $50 million or 8.5 million shares, and closed its first NYSE session at $11.50, down 0.43%, before trading near $11.78 early Thursday, as investors weigh whether the uplisting and buyback will boost demand amid ongoing federal cannabis policy uncertainty.
Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

11 June 2026
Propanc Biopharma shares soared as much as 392% after authorizing up to $5 million in stock buybacks—exceeding its prior $3.1 million equity value—even as it reported just $443,702 in cash and flagged going-concern risks, with investors now focused on whether its lead cancer drug PRP will advance to a planned Phase 1b trial this year.
Tesla stock slips after SEC filing on top exec pay; Wall Street parses inflation
Previous Story

Tesla stock slips after SEC filing on top exec pay; Wall Street parses inflation

Google stock (GOOG) rises after-hours on Apple’s Gemini-Siri deal as earnings near
Next Story

Google stock (GOOG) rises after-hours on Apple’s Gemini-Siri deal as earnings near

Go toTop